Back to Search Start Over

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients

Authors :
Zhao Yang
Xiaodan Wang
Mengyue Niu
Qiao Wei
Huizhu Zhong
Xiaoyan Li
Weihong Yuan
Wenli Xu
Shuo Zhu
Shengyuan Yu
Jun Liu
Jianzhou Yan
Wenyan Kang
Peijian Huang
Source :
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Publication Year :
2024
Publisher :
BMC, 2024.

Abstract

Abstract Background Rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries. However, there is a lack of prospective real-world evidence for the use of rimegepant in Chinese migraine patients. Methods This was a single-arm, prospective, real-world study. While taking rimegepant to treat migraine attacks as needed, eligible participants were asked to record their pain intensity, functional ability, and accompanying symptoms for a single attack at predose and 0.5, 1, 2, 24, and 48 h postdose via a digital platform. Adverse events (AEs) during the rimegepant treatment period were recorded and analysed. The percentages of participants who experienced moderate to severe pain at predose and 0.5, 1, 2, 24, and 48 h postdose were assessed. Additionally, the percentages of participants who reported better/good outcomes in terms of pain intensity, functional ability, and accompanying symptoms at 0.5, 1, 2, 24, and 48 h postdose were analysed. In addition, the total cohort (full population, FP) was stratified into a prior nonresponder (PNR) group to observe the effectiveness and safety of rimegepant for relatively refractory migraine and a rimegepant and eptinezumab (RE) group to observe the effectiveness and safety of the combination of these drugs. Results By November 24th, 2023, 133 participants (FP, n = 133; PNR group, n = 40; RE group, n = 28) were enrolled, and 99 participants (FP, n = 99; PNR group, n = 30; RE group, n = 23) were included in the analysis. Rimegepant was effective in treating migraine in the FP and both subgroups, with a significant decreasing trend in the percentages of participants experiencing moderate to severe pain postdose (p

Details

Language :
English
ISSN :
11292377
Volume :
25
Issue :
1
Database :
Directory of Open Access Journals
Journal :
The Journal of Headache and Pain
Publication Type :
Academic Journal
Accession number :
edsdoj.fc0d26e8244b48c6bde011dd3c590353
Document Type :
article
Full Text :
https://doi.org/10.1186/s10194-024-01873-5